Histogenics files for an initial public offering of its stock, aiming to raise up to $65 million as it begins Phase III testing of its knee cartilage product NeoCart.
Histogenics filed for an initial public offering, aiming to raise up to $65 million as it begins Phase III testing of its knee cartilage product NeoCart.
The regenerative medicine company plans to list its shares on the NASDAQ exchange under the symbol HSGX.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1semLR7
Cap comentari:
Publica un comentari a l'entrada